2
Registered trials
1
Recruiting
2
Unique sponsors
2
Unique IMPs
0
Commercial trials
Drug classes (ATC)
—
ATC code not specified
1
L
Oncology (ATC L)
1
Mechanism of action (INN-stem analysis)
Checkpoint inhibitor (PD-L1)
1 substance
Checkpoint inhibitor (CTLA-4)
1 substance
Phase I/II:
1
Phase I:
1
Phase I/II
1 trial-
EndedInstitut Gustave Roussy AcademicDURVALUMAB; TREMELIMUMAB
Phase I
1 trial-
RecruitingKarolinska University Hospital AcademicIMP not specified
Sponsor activity
| Sponsor | Type | Trials | Phases | Recruiting |
|---|---|---|---|---|
| Karolinska University Hospital | Academic | 1 | Phase I | 1 |
| Institut Gustave Roussy | Academic | 1 | Phase I/II | 0 |
New trials by year
2025
1